Treats relapsing forms of multiple sclerosis (MS). ANDA 207991, held by Accord Hlthcare. Fingolimod Hydrochloride.
As of Nov 16, 2026, ANDA 207991 (Fingolimod Hydrochloride), held by Accord Hlthcare, was first approved by FDA on Oct 28, 2020, with 3 approved supplements and 0 published complete response letters.
Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fingolimod HydrochlorideEQ 0.5MG BASE · capsule;oral | Fingolimod Hydrochloride | Rx |
| Sep 25, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 19, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 30, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 28, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters